samedan logo

 
 
spacer
home > advertise
ADVERTISING OPPORTUNITIES
Why Advertise with Samedan?

 

Samedan's range of specialist titles spans the full spectrum of pharmaceutical development, from innovation to patient, and is designed to meet the broad
needs of an industry built on high-quality information, communication, and expertise.

With a history going back more than a decade, Samedan's clients range from long-established industry leaders to the most recent start-ups and university spin-outs.
Many clients have advertised across our entire range for years and have come to
appreciate a strong and cooperative relationship with us.

Samedan is committed to providing the perfect editorial platform for your advert.
That is why our featured articles take an opinion-led, non-promotional view of the industry. This ensures that every advert enjoys maximum impact with each title's readership of 10,000+ key decision makers.

For further information about each of our titles, follow the links below. Each of our advertising executives can be contacted at the email addresses below and will be
pleased to discuss how Samedan can meet your needs.

Tel: +44 (0)20 7724 3456
Fax: +44 (0)20 7403 7747

European Pharmaceutical Contractor
Simon Caplan: simon@samedanltd.com

European BioPharmaceutical Review
Helga Schweissguth: helga@samedanltd.com

International Clinical Trials
Simon Caplan: simon@samedanltd.com

Pharmaceutical Manufacturing and Packing Sourcer
Simon Caplan: simon@samedanltd.com

Innovations in Pharmaceutical Technology
Helga Schweissguth: helga@samedanltd.com



 

spacer

News and Press Releases

ProteoGenix, Aseem Healthcare, and Trident Biopharm Solutions Announce a New Antibody Cocktail Effective Against Major Variants of SARS-CoV-2

Schiltigheim, France 7 June 2022 Life Science Newswire ProteoGenix (market-leading antibody provider), Aseem Healthcare (global healthcare company), and Trident Biopharm Solutions (life science consultancy agency) are pleased to announce the development of a new antibody cocktail effective against major variants of SARS-CoV-2. The cocktail of four fully human neutralizing antibodies (AH-5-COV) was generated by screening the plasma of a COVID-19 survivor using ProteoGenixs phage display platform. The new treatment is undergoing preclinical evaluation and will be ready to start clinical trials in 2 months.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement